A Single Point of Access for frontline practitioners
PAINWeekEnd Indianapolis 2019 | Saturday 3/30/19
This is a 1-day meeting and will provide 6 CE/CME credits.
Practicing Healthcare Professionals: $129
In order to maintain the clinical nature of the conference, nonclinicians—including, but not limited to, office managers, billing specialists, receptionists, and administrative staff; guests, spouses, friends, and/or family members—may not attend PAINWeekEnd.
Unfortunately, we do not have discounts available on hotel rooms. Please contact the hotel directly should you require accommodations.
Indianapolis Marriott North
3645 River Crossing Parkway
Indianapolis, IN 46240
Get Directions using Google Maps
Download a printable version of the agenda >>
Faculty and courses are subject to change. Please refer to the online agenda below for the most recent course descriptions.
To view the agenda below, click on the + sign next to the day of the conference to expand the conference agenda. Click on the + signs within the agenda to view the course description, UAN number, and AANP pharmacology credits.
*not certified for credit
Coffee will be served.
In order to successfully clinically manage pain, it is essential to begin with an understanding of the underlying mechanisms responsible for its generation. A skillful approach based upon better knowledge concerning the anatomical structures, pathways, and events that result in pain is more likely to lead to effective clinical management of pain. The discussion will include an overview of medication classes typically considered for pain and the pathways they affect.
When tapering opioid therapy, frontline practitioners may at times be faced with chronic pain patients suffering from undiagnosed mental health disorders. In most cultures, the majority of mental health cases go unrecognized in primary care settings. About 60% of previously undetected cases could have been recognized if the patients had been evaluated for a mental health disorder. Research has shown that chronic pain is most often associated with depression, anxiety, and somatoform, personality, and substance use disorders, but less is known about the relationship with other conditions, such as schizophrenia spectrum/psychotic, sleep-wake, bipolar, neurocognitive, obsessive compulsive, and dissociative disorders. The purpose of this presentation is to help providers learn more about mental health disorders, how they are defined, and how the definitions have changed in the latest Diagnostic and Statistical Manual of Mental Disorders. The results of a pilot study looking at the prevalence rates of these new dsm disorders among patients who suffer from chronic pain will be delineated.
The shift away from opioid use in medication management for chronic pain has changed the dynamic of opioid prescribing in many ways. Now, more than ever, prescribers are under the microscope regarding selection of opioid and dose as well as clinical documentation and appropriate action based on findings during the patient visit. Risks of opioids outweighing the benefits due to lack of effect, adverse effects, or aberrant behavior are just some of the possible justifications to consider opioid tapering. There are other instances when there is outright dangerous or illegal behavior that justifies discontinuation of opioids. This lecture will review different patient situations and discuss when to taper or discontinue opioids and how to implement the change in opioid therapy.
Lunch will be served.
Sponsored by SCILEX.
There is a growing opioid epidemic and our role as providers and patient leaders in the community cannot be overstated. We need to recognize the growing burden of this problem as well as the role of all stakeholders in addressing the opioid epidemic in their communities. What is the prevalence, nationally and locally, for opioid use and prescribing? Where are the growing pockets and populations of opioid use? What is the Drug Enforcement Agency’s perspective from the front lines? In this course you learn how to apply knowledge of acute and chronic pain pathways and underlying mechanisms to clinical assessment and appropriate management of pain. Through the use of a 3D presentation, the differences between acute and chronic pain pathways and pain points and specific targets for opioids—appropriate and inappropriate—will be demonstrated. We will evaluate current clinical workflows for opioid prescribing, incorporating 2 best practice strategies to optimize safe and competent prescribing and minimize potential for abuse and diversion. Discussed will be working with patients to develop multimodal pain strategies; how to minimize the risk for diversion and abuse; and safe disposal of medications. After this course, you will be able to access resources and guidelines to recognize and treat patients with opioid use disorder and integrate into practice concepts from novel programs in the community to address opioid overdose and treat patients with opioid use disorder.
Presented by CME Outfitters and USF Health. Supported by an educational grant from Johnson & Johnson.
Click here to download the slides for this presentation.
Diagnostic testing is an integral component for the differential diagnosis. In routine clinical practice there has been a tendency for clinical examinations to become more cursory, largely influenced by increasing demands of time and patient expectations of technological advances. The end result may arguably lead to an overreliance on technology for basic clinical diagnosis. The purpose of this session is 2-fold. It is meant to provide a review and, for some, an introduction to basic structural and functional studies used for the diagnosis of pain related problems. Attention will also be given to the limitations of such studies and the importance of establishing clinical relevance to their findings. Factors that adversely affect clinical management potentially resulting in failed treatment will be discussed as well as best practices when utilizing such studies to help enhance clinical outcomes for treatment.
The gabapentinoids are a popular class of medications among prescribers for use in chronic pain and various other neurological conditions. In fact, prescription rates for both gabapentin and pregabalin have increased in the United States and other countries in recent years. However, these medications have a street value to a newer niche of users, including patients taking them at megadoses to enhance the effects of other psychotropic drugs, and other patients taking them to manage or mitigate opioid withdrawal symptoms and possibly even opioid cravings. While pregabalin is already classified as a controlled substance, gabapentin does not yet carry this classification. In response to rising abuse, various states and regulatory bodies are considering changes to enhance patient safety and protect the provider’s license. Learn what changes you should make to your practice, if any, in light of the growing abuse of gabapentinoids and how to identify patients potentially abusing them.
To accompany and enrich your experience at the PAINWeekEnd conference, be sure to attend one or more of the sponsored programs, which are scheduled during breakfast, lunch, and afternoon "Brain Food" time slots in the schedule. There is NO ADDITIONAL CHARGE to attend these program sessions!